Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
03.11.2022 - New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) - Centessa Pharmaceuticals plc ... Seite 1